Clinical trial
Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After…
NCT00215163 · Duke University, Other · Completed
Key facts
| NCT number | NCT00215163 |
|---|---|
| Title | Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy |
| Official title | Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy |
| Lead sponsor | Duke University, Other |
| Collaborators | GlaxoSmithKline Industry Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Stress Disorders, Post-Traumatic |
| Intervention type | Drug |
| Interventions | Cognitive-behavioral therapy and paroxetine-CR |
| Enrollment | 17 |
| Start date | Dec 1, 2002 |
| Completion | Jun 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: